Salt form of tyrosine kinase inhibitor

US9018242B2 · kind B2 · utility

Assignee

• JIANGSU SIMCERE PHARMACEUTICAL CO., LTD. · CN

Inventors

• Feng TANG · 安丰镇, CN
• Qiu JIN · Cupertino, US
• Wei Li · Lexington, US
• Tian Zhu · Fremont, US
• Yang Hu · Brookline, US
• Feng Shao · Beijing, CN

Key dates

• Filing date: Sep 11, 2013
• Grant date: Apr 28, 2015
• Expiry date: Sep 11, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D209/42
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided are acid addition salts of (Z)—N-[2-(diethylamino)ethyl]-2-methyl-7-(1,2 -dihydro-5-fluoro-2-oxo-3H-indol-3-ylidene)-4,5,6,7-tetrahydro-1H-indol-3-carboxamide, wherein the salt comprising at least one of a number of salts including L-malate, hydrochloride, phosphate, L-tartrate, benzenesulfonate, sulfate, methanesulfonate, succinate, citrate, fumarate, p-toluenesulfonate, hydrobromate, L-mandelate, lactate, acetate or maleate salt. Also provided is a pharmaceutical composition comprising the salt compounds, and a method of treatment by administering a therapeutically effective amount of the salt compounds as preparation of medicaments.